Lyell Immunopharma, Inc.
LYEL
$12.90
$0.201.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -52.31% | -40.98% | -34.92% | 11.11% | -4.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -52.31% | -40.98% | -34.92% | 11.11% | -4.41% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -52.31% | -40.98% | -34.92% | 11.11% | -4.41% |
| SG&A Expenses | -22.72% | -13.27% | -3.25% | -7.90% | -14.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -35.21% | -33.47% | -48.52% | -42.42% | -49.57% |
| Total Operating Expenses | -15.28% | -9.69% | -8.45% | -6.03% | -8.23% |
| Operating Income | 15.27% | 9.68% | 8.44% | 6.03% | 8.23% |
| Income Before Tax | 26.34% | 19.98% | -59.65% | -57.61% | -46.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.34% | 19.98% | -59.65% | -57.61% | -46.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.34% | 19.98% | -59.65% | -57.61% | -46.50% |
| EBIT | 15.27% | 9.68% | 8.44% | 6.03% | 8.23% |
| EBITDA | 12.86% | 6.58% | 6.50% | 4.77% | 7.99% |
| EPS Basic | 46.64% | 39.69% | -38.91% | -42.30% | -34.24% |
| Normalized Basic EPS | 34.15% | 20.34% | 18.98% | 13.28% | 14.19% |
| EPS Diluted | 46.64% | 39.69% | -38.91% | -42.30% | -34.24% |
| Normalized Diluted EPS | 34.15% | 20.34% | 18.98% | 13.28% | 14.19% |
| Average Basic Shares Outstanding | 38.86% | 30.66% | 21.35% | 11.19% | 7.75% |
| Average Diluted Shares Outstanding | 38.86% | 30.66% | 21.35% | 11.19% | 7.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |